Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 booster study after mRNA vaccination and/or prior SARS-CoV-2 infection
NL-OMON51640Phase 3Completed
- Sponsor
- Valneva
- Start
- May 2022
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of VLA2001 in coronavirus disease 2019 (COVID-19) (9 cohorts), sponsored by Valneva. Primary endpoints: GMT fold-rise for neutralising antibodies against SARS-CoV-2 at Day 15 and Frequency and severity of solicited adverse events within 7 days. Started May 2022; status: completed.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51640.